BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology institution redefining the frontier of precision medicine done its Precision Oncology 2.0 strategy, contiguous announced the enactment of its Clinical Scientific Advisory Board (“Clinical SAB”). The Clinical SAB volition complement the heavy expertise of Scorpion Therapeutics’ enactment team, world founders, Board of Directors, and the antecedently announced Discovery SAB to enactment the institution successful advancing its portfolio of perchance first- oregon best-in-class merchandise candidates for the attraction of cancer.
The members of Scorpion’s Clinical SAB include:
- Alexander Eggermont, M.D., Ph.D., Professor of Immunotherapy astatine University Medical Center Utrecht and Chief Scientific Officer of the Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands, arsenic good arsenic Emeritus Professor of Oncology astatine Paris-Sud University and Emeritus Professor of Oncological Surgery astatine Erasmus University Rotterdam.
- Keith Flaherty, M.D., Director of Clinical Research astatine the Massachusetts General Hospital Cancer Center, Professor of Medicine astatine Harvard Medical School and co-founder of Scorpion Therapeutics.
- Pasi A. Jänne, M.D, Ph.D., Director of the Lowe Center for Thoracic Oncology, Belfor Center for Applied Cancer Science and Chen-Huang Center for EGFR Mutant Lung Cancers astatine the Dana Farber Cancer Institute and Professor of Medicine astatine Harvard Medical School.
- Joyce O’Shaughnessy, M.D., Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research astatine Baylor-Sammons Cancer Center and The US Oncology Network
- Josep Tabernero, M.D., Ph.D., Director of the Vall d´Hebron Institute of Oncology (VHIO), arsenic good arsenic Co-Director of VHIO’s Research Unit for Molecular Therapy of Cancer and Head of the Gastrointestinal and Endocrine Tumors Group, and Head of the Medical Oncology Department of the Vall d’Hebron University Hospital.
“We are excited to denote the enactment of our Clinical SAB and to invited these world-renown physician-scientists to the Scorpion team,” said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion Therapeutics. “Each subordinate is simply a pioneer successful the objective improvement of caller medicines that person had transformational interaction for patients We look guardant to their guidance and contributions arsenic we beforehand our increasing portfolio toward the clinic, with the eventual extremity of optimizing and delivering transformational next-generation precision medicines for larger populations of crab patients.”
“As a whole, this radical has devoted their careers to accelerating the improvement of personalized crab medicines and volition bring america galore important insights arsenic we enactment to beforehand our pb programs into the clinic,” said Dr. Michael Streit, M.D., Chief Medical Officer of Scorpion Therapeutics and Chairman of the company’s Clinical SAB. “It is an perfect clip to found this advisory board, connected the heels of naming our 2nd improvement campaigner and arsenic we are advancing 2 perchance best-in-class programs, STX-478, targeting mutant PI3Kα and STX-721, targeting mutant EGFR Exon 20, toward investigational caller cause (IND) applications successful 2023. We look guardant to partnering with these esteemed advisors to assistance finalize our improvement plans and enactment our maturation into a clinical-stage company.”
Alexander Eggermont, M.D., Ph.D.
Dr. Eggermont is the Professor of Immunotherapy astatine University Medical Center Utrecht and the Chief Scientific Officer of the Princess Máxima Center for Pediatric Oncology. He antecedently served arsenic the General Director of the Gustave Roussy Cancer Center Campus Grand Paris, wherever helium developed Europe’s largest Phase 1-2 cause and immunotherapy improvement program. Dr. Eggermont is besides an Emeritus Professor of Oncology astatine Paris-Sud University, Emeritus Professor of Oncological Surgery astatine Erasmus University Rotterdam and a Fellow of the National Institutes of Health’s National Cancer Institute (NIH-NCI). Dr. Eggermont has served arsenic President of ECCO, President of the EORTC, was a subordinate of the Board of Directors of ASCO, served connected the Editorial Board of the Journal of Clinical Oncology, and is presently Editor-in-Chief of the European Journal of Cancer. He has published much than 900 peer-reviewed papers and his expertise has been acknowledged by galore nonrecreational awards passim his career.
Keith Flaherty, M.D.
Dr. Flaherty is Director of Clinical Research astatine the Massachusetts General Hospital Cancer Center and Professor of Medicine astatine Harvard Medical School. As described successful the much than 300 adjacent reviewed superior probe reports helium has authored oregon co-authored, Dr. Flaherty and his colleagues made respective seminal observations that person defined the attraction of melanoma erstwhile they established the efficacy of BRAF, MEK and combined BRAF/MEK inhibition successful patients with metastatic melanoma successful a bid of New England Journal of Medicine articles for which Dr. Flaherty was the archetypal oregon elder author. He is the main researcher of the NCI MATCH trial, the archetypal NCI-sponsored proceedings assigning patients to targeted therapy autarkic of tumor benignant connected the ground of DNA sequencing detection of oncogenes. Dr. Flaherty joined the NCI Board of Scientific Advisors successful 2018 and AACR Board of Directors successful 2019. He serves arsenic editor-in-chief of Clinical Cancer Research. Dr. Flaherty co-founded Loxo Oncology successful 2013 and served connected the committee of directors done the acquisition by Eli Lilly successful 2019. He co-founded X4 Pharmaceuticals (NASDAQ: XFOR) and privately held Strata Oncology (2015), Apricity Oncology (2017), C-Reveal (2020). He serves connected the boards of directors for Clovis Oncology, Checkmate Pharmaceuticals, Kinnate BioPharma and Scorpion Therapeutics.
Pasi A. Jänne, M.D., Ph.D.
Dr. Jänne is the manager of the Lowe Center for Thoracic Oncology, the Director of the Belfer Center for Applied Cancer Science and the Director of the Chen-Huang Center for EGFR Mutant Lung Cancers astatine Dana-Farber Cancer Institute. His main probe interests see studying the therapeutic relevance of oncogenic alterations successful lung cancer. He was 1 of the co-discoverers of epidermal maturation origin receptor (EGFR) mutations and has led the improvement of therapeutic strategies for patients with EGFR mutant lung cancer. Dr. Jänne has received respective awards for his research, including from Uniting Against Lung Cancer, American Lung Association, and the Bonnie J. Addario Lung Cancer Foundation. He is an elected subordinate to the American Society of Clinical Investigation (2008), American Association of Physicians (2016), and the Finnish Academy of Science and Letters (2016). Dr. Jänne is the recipient of 2010 American Association of Cancer Research Richard and Hinda Rosenthal Memorial Award and a subordinate of the 2010 AACR Team Science Award, American Cancer Research Clinical Research Professorship (2017), Waun Ki Hong Award for Outstanding Achievement successful Translational and Clinical Cancer Research from the American Association for Cancer Research (2018), Translational Research Award from the European Society for Medical Oncology (2018), R35 - Outstanding Investigator Award from the National Cancer Institute (2018), and Science of Oncology Award from the American Society of Clinical Oncology (2020).
Joyce O’Shaughnessy, M.D.
Dr. O’Shaughnessy is Director of Breast Cancer Research astatine Baylor-Sammons Cancer Center and Chair of Breast Cancer Research for US Oncology. She is simply a Diplomate of the American Board of Internal Medicine with subspecialty certification successful aesculapian oncology. She received her M.D. from Yale University Medical School, and completed her internship and residency successful interior medicine astatine Massachusetts General Hospital. She concluded a fellowship successful aesculapian oncology astatine the National Cancer Institute successful 1987 and was a Senior Investigator determination until 1995. Dr. O’Shaughnessy is the recipient of respective awards including: Giants of Cancer Care: Community Outreach/Education Award; Baylor University Medical Center: Staff Chief’s award; Holy Cross College: Santae Crucis Award (Distinguished Alumni Award): Public Health Service Special Service: Development of the Consensus Statement connected Cancer Drug Approval Endpoints Award; and the Yale Medical School: Francis Parker Award (Faculty Choice for Most Promising Clinician). She is simply a subordinate of the American Association for Cancer Research and the American Society of Clinical Oncology. Dr. O’Shaugnessy is the Founder of The School of Breast Oncology.
Josep Tabernero, M.D., Ph.D.
Dr. Tabernero is presently the Head of the Medical Oncology Department astatine the Vall d’Hebron Barcelona Hospital Campus and Director of the Vall d’Hebron Institute of Oncology (VHIO). He besides co-directs the VHIO´s Gastrointestinal and Endocrine Tumours Group and the Research Unit for Molecular Therapy of Cancer (UITM) and is Principal Investigator of respective Phase 1 pharmacodynamic studies and translational projects with molecular targeted therapies, arsenic good arsenic Phase 2 and 3 studies with caller chemotherapeutics. His radical aims astatine potentiating molecular therapies targeting circumstantial oncoproteins and accelerating much effectual personalized crab medicines for patients displaying familial lesions oregon pathway disregulation. One of his team´s main objectives is to found caller predictive markers of effect to anti-cancer therapies and place markers of superior absorption (de novo) and secondary treatment. Dr. Tabernero serves connected the Editorial Boards of assorted apical tier journals including Annals of Oncology, ESMO Open, Cancer Discovery and Clinical Cancer Research. He has authored oregon co-authored astir 550 peer-reviewed papers. He has served arsenic President of the European Society for Medical Oncology (ESMO) during the 2018 – 2019 term. He is besides subordinate of the AACR and ASCO, and has been appointed arsenic subordinate of respective Educational and Scientific Committees of ESMO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, and ESMO-GI/WCGIC meetings.
About Scorpion Therapeutics
Scorpion Therapeutics is simply a pioneering oncology institution redefining the frontier of precision medicine to present optimized and transformational therapies for larger populations of patients with cancer, a strategy Scorpion Therapeutics refers to arsenic Precision Oncology 2.0. Scorpion Therapeutics has built a proprietary and afloat integrated level of the astir precocious technologies crossed crab biology, medicinal chemistry, and information sciences, with the extremity of consistently and rapidly creating exquisitely selective tiny molecule compounds against an unprecedented spectrum of targets. Scorpion Therapeutics aims to leverage its level to beforehand a wide pipeline of wholly owned, optimized compounds crossed 3 people categories: best-in-class molecules targeting validated oncogene targets; first-in-class molecules for antecedently undruggable targets; and first-in-class molecules for caller crab targets. For much information, sojourn www.scorpiontx.com.
English (US)